Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program to Make Novel Presbyopia Therapy More Accessible and Affordable

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI™, the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia. Why Direct-to-Patient Access Matters for Presbyopia Patients Access and adherence remain persistent challenges in ophthalmology, where treatments are o